PMID- 38137901
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231225
IS  - 2075-1729 (Print)
IS  - 2075-1729 (Electronic)
IS  - 2075-1729 (Linking)
VI  - 13
IP  - 12
DP  - 2023 Dec 5
TI  - Real-World Data on Second-Line Therapy with Ramucirumab for Metastatic Gastric 
      Cancer: A Two-Center Study on Romanian Population.
LID - 10.3390/life13122300 [doi]
LID - 2300
AB  - (1) Background: Following the results of RAINBOW and REGARD trials, ramucirumab 
      was approved as the standard second-line treatment for patients with advanced or 
      metastatic gastric or gastroesophageal junction (GEJ) cancer, alone or in 
      combination with paclitaxel. The present study aimed to evaluate the efficacy and 
      safety of ramucirumab in the Romanian population during every-day clinical 
      practice. (2) Methods: A two-center, retrospective, observational study evaluated 
      patients with metastatic gastric and GEJ cancer treated with ramucirumab 
      monotherapy or associated with paclitaxel. The patients were treated between 2018 
      and 2022 in two Romanian centers as follows: 18 patients underwent treatment with 
      ramucirumab monotherapy, while 51 received the combined treatment regimen. Study 
      endpoints included median progression-free survival (PFS), median overall 
      survival (OS), and the evaluation of treatment-induced adverse events (AEs). (3) 
      Results: In the study cohort (n = 69), the most frequent treatment-induced AE in 
      the ramucirumab plus paclitaxel arm was hematological toxicity; the most common 
      AE for patients treated with ramucirumab monotherapy was fatigue and headache. 
      Overall, the median PFS was 4.7 months (95% CI: 3.4-5.9 months) and median OS was 
      18.23 months (95% CI: 15.6-20.7 months). PFS was correlated with the number of 
      treatment cycle administrations, Eastern Cooperative Oncology Group performance 
      status at treatment initiation, and metastatic site (visceral vs. peritoneal). OS 
      was correlated with the number of treatment cycles administered and human 
      epidermal growth factor receptor-2 status. (4) Conclusions: The results support 
      the previously described toxicity profile for ramucirumab monotherapy or 
      associated with paclitaxel and demonstrated a relatively superior median PFS.
FAU - Galos, Diana
AU  - Galos D
AD  - Department of Medical Oncology, The Oncology Institute Prof. Dr. Ion Chiricuta, 
      400015 Cluj-Napoca, Romania.
FAU - Balacescu, Loredana
AU  - Balacescu L
AD  - Department of Genetics, Genomics and Experimental Pathology, The Oncology 
      Institute Prof. Dr. Ion Chiricuta, 400015 Cluj-Napoca, Romania.
FAU - Vidra, Radu
AU  - Vidra R
AUID- ORCID: 0000-0001-7968-908X
AD  - Postgraduate Program for Bio-Behavioral Integrative Medicine, Babes-Bolyai 
      University, 400084 Cluj-Napoca, Romania.
AD  - Department of Medical Oncology, Regional Institute of Gastroenterology and 
      Hepatology Prof. Dr. Octavian Fodor, 400162 Cluj-Napoca, Romania.
FAU - Sur, Daniel
AU  - Sur D
AUID- ORCID: 0000-0002-0926-4614
AD  - Department of Medical Oncology, The Oncology Institute Prof. Dr. Ion Chiricuta, 
      400015 Cluj-Napoca, Romania.
AD  - Department of Medical Oncology, University of Medicine and Pharmacy "Iuliu 
      Hatieganu", 400012 Cluj-Napoca, Romania.
LA  - eng
PT  - Journal Article
DEP - 20231205
PL  - Switzerland
TA  - Life (Basel)
JT  - Life (Basel, Switzerland)
JID - 101580444
PMC - PMC10744814
OTO - NOTNLM
OT  - gastric cancer
OT  - gastroesophageal junction cancer
OT  - metastatic disease
OT  - paclitaxel
OT  - ramucirumab
OT  - second-line treatment
COIS- The authors declare no conflict of interest.
EDAT- 2023/12/23 12:44
MHDA- 2023/12/23 12:45
PMCR- 2023/12/05
CRDT- 2023/12/23 01:12
PHST- 2023/10/24 00:00 [received]
PHST- 2023/11/24 00:00 [revised]
PHST- 2023/12/01 00:00 [accepted]
PHST- 2023/12/23 12:45 [medline]
PHST- 2023/12/23 12:44 [pubmed]
PHST- 2023/12/23 01:12 [entrez]
PHST- 2023/12/05 00:00 [pmc-release]
AID - life13122300 [pii]
AID - life-13-02300 [pii]
AID - 10.3390/life13122300 [doi]
PST - epublish
SO  - Life (Basel). 2023 Dec 5;13(12):2300. doi: 10.3390/life13122300.